Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health, Inc.: Progress Since May 2020
Completed e nrollment in 3 p ivotal c linical t rials; multiple data read outs in Q4 2021 Released meaningful abaloparatide histomorphometry data at recent ASBMR meeting Completed two business development transactions with existing oncology asset s Repositioned commercial effort to focus on high
View HTML
Toggle Summary Radius Health to Announce Third Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, November 5, 2020
WALTHAM, Mass. , Oct. 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its third quarter financial results on Thursday, November 5, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
View HTML
Toggle Summary Peter A. Schwartzman Joins Radius Health, Inc.
Schwartzman joins the newly formed Capital, Strategy, & Transactions Group WALTHAM, Mass. , Oct. 06, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed
View HTML
Toggle Summary Radius Health Divests RAD 140 Program to Ellipses Pharma
Business development step enables molecule to move forward Program progression will be at no financial risk to Radius Reinforces Radius ’   focus on execution of core business WALTHAM, Mass. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that the company has
View HTML
Toggle Summary Radius Health & Menarini Group Provide Elacestrant Update
Target enrollment milestone reached in the Phase 3 EMERALD study Life cycle planning advancing in parallel with current Phase 3 monotherapy program WALTHAM, Mass. and FLORENCE, Italy , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) and the
View HTML
Toggle Summary Radius Health Provides Business Update
Organizational Change   with in Finance Function Creates Capital, Strategy &   Transac tions Group WALTHAM, Mass. , Sept. 24, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that Jose (Pepe) Carmona will be stepping down as Chief Financial
View HTML
Toggle Summary Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting
Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan WALTHAM, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American
View HTML
Toggle Summary Radius Health: Enrollment Completed for Phase 3 wearABLe trial
Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skin Trial success followed by regulatory approval would provide a completely unique drug administration option for postmenopausal women with osteoporosis.
View HTML
Toggle Summary Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference
WALTHAM, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management will host virtual meetings with investors during the Citi 15 th  Annual BioPharma Virtual
View HTML
Toggle Summary Radius Health Provides Business Update
TYMLOS ® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent life Enrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males with osteoporosis WALTHAM, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius”
View HTML